Levels of minimal residual disease in chronic myelogenous leukemia (CML) patients in complete cytogenetic remission after interferon-alpha-therapy correlate with risk of relapse.

被引：0
|
作者：
Hochhaus, A
Lin, F
Reiter, A
Skladny, H
Shepherd, PCA
Sill, H
Allan, NC
Hehlmann, R
Goldman, JM
Cross, NCP
机构：
[1] UNIV HEIDELBERG,KLINIKUM MANNHEIM,MED KLIN 3,D-6900 HEIDELBERG,GERMANY
[2] HAMMERSMITH HOSP,LRF LEUKAEMIA UNIT,LONDON,ENGLAND
[3] MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND
[4] GRAZ UNIV,DEPT HAMATOL,A-8010 GRAZ,AUSTRIA
来源：
EXPERIMENTAL HEMATOLOGY | 1996年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：579 / 579
页数：1
相关论文
共 50 条
  • [21] T-cell specific immunity in chronic myelogenous leukemia: Restoration in complete cytogenetic remission with interferon-alpha.
    Reuben, J
    Lee, BN
    Gao, H
    Kantajian, H
    Talpaz, M
    BLOOD, 2000, 96 (11) : 737A - 737A
  • [22] PREDICTING COMPLETE CYTOGENETIC RESPONSE IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED WITH RECOMBINANT INTERFERON-ALPHA
    MAHON, FX
    MONTASTRUC, M
    FABERES, C
    REIFFERS, J
    BLOOD, 1994, 84 (10) : 3592 - 3594
  • [23] Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse
    Kim, YJ
    Kim, DW
    Lee, S
    Min, CK
    Goh, HG
    Kim, SH
    Lee, JY
    Kim, YL
    Kim, HJ
    Kim, HJ
    Lee, JW
    Kim, TG
    Min, WS
    Kim, CC
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (10) : 718 - 725
  • [24] Negativation of BCR-ABL loading in chronic myelogenous leukemia (CML) patients with sustained complete cytogenetic remission after imatinib treatment.
    Colombat, M
    Chollet, C
    Marit, G
    Roche, C
    Preudhomme, C
    Reiffers, J
    Praloran, V
    Mahon, FX
    BLOOD, 2003, 102 (11) : 417A - 417A
  • [25] RESULTS OF RECOMBINANT ALPHA-2-C-INTERFERON THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML)
    KUHRER, I
    LINKESCH, W
    LUDWIG, H
    GISSLINGER, H
    BLUT, 1987, 55 (04): : 390 - 390
  • [26] Minimal residual disease in patients with hairy cell leukemia in complete remission: Comparison of 2-chlorodeoxyadenosine with 2-deoxycoformycin and prediction of early relapse.
    Tallman, M
    Hakimian, D
    Wheaton, S
    Kopecky, K
    Wollins, E
    Foucar, K
    Cassileth, P
    Habermann, T
    Grever, M
    Peterson, LC
    BLOOD, 1995, 86 (10) : 1390 - 1390
  • [27] MINIMAL RESIDUAL DISEASE-FREE COLLECTION OF PERIPHERAL-BLOOD STEM-CELLS IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AFTER INTERFERON-ALPHA THERAPY
    ROVITO, MA
    LUCE, M
    NOWELL, PC
    SIEGEL, JE
    NEILAN, BA
    BESA, EC
    BLOOD, 1994, 84 (10) : A351 - A351
  • [28] PREDICTING COMPLETE CYTOGENETIC RESPONSE IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED WITH RECOMBINANT INTERFERON-ALPHA - REPLY
    OZER, H
    BLOOD, 1994, 84 (10) : 3594 - 3594
  • [29] Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia
    Maloisel, F
    Uettwiller, F
    Laplace, A
    Lioure, B
    Herbrecht, R
    Mark, M
    Dufour, P
    CANCER GENETICS AND CYTOGENETICS, 1999, 113 (02) : 172 - 176
  • [30] Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy
    Hochhaus, A
    Reiter, A
    Skladny, H
    Reichert, A
    Saussele, S
    Hehlmann, R
    ADVANCES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND MOLECULAR THERAPY, 1998, 144 : 36 - 45
12345